Inclusion Criteria:

- Provision of signed, written and dated consent prior to any study specific procedures

- Male or female, aged 18 years or older

- Histological or cytological confirmation of locally advanced or metastatic NSCLC
(IIIB-IV)

- Female patients must not be breast-feeding and have a negative pregnancy test prior
to start of dosing or must have evidence of non-child-bearing potential

- Patients must be eligible to receive treatment with the platinum doublet combination
with which selumetinib is being combined and in accordance with the local product
information

Exclusion Criteria:

- Prior chemotherapy or other systemic anti-cancer treatment for advanced NSCLC.

- Prior surgery or radiotherapy within 6 months or palliative radiotherapy within 4
weeks of start of study treatment.

- Female patients who are breast-feeding or male or female patients of reproductive
potential who are not employing an effective method of birth control

- Another primary malignancy within 5 years of starting study treatment, except for
adequately treated basal or squamous cell carcinoma of the skin or cancer of the
cervix in situ.

- As judged by the Investigator, any evidence of severe or uncontrolled systemic
diseases, active bleeding diatheses, renal transplant, or active infection